Company profile

Vaxart, Inc.

Pipeline4 assets

VXA-CoV2-3.3VXA-CoV2-3.3 / SARS-CoV-2 / Oral recombinant adenovirus vaccine / Infectious Diseases
COVID-19
Norovirus Oral Vaccine CandidateNorovirus (GI.1 and GII.4) / Oral recombinant adenovirus vaccine / Infectious Diseases
Norovirus InfectionAcute Gastroenteritis
Seasonal Influenza Oral Vaccine CandidateVXA-A1 / Influenza Virus / Oral recombinant adenovirus vaccine / Infectious Diseases
Seasonal Influenza
HPV Therapeutic Vaccine CandidateHuman Papillomavirus (HPV) / Oral recombinant therapeutic vaccine / Oncology
HPV-associated Cancers / Immuno-oncology

Latest news18 items

Jul 6, 2026

Vaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 Vaccine

No vaccine-related serious adverse events (SAEs) or sustained Grade 3 or higher adverse events related to the vaccine reported SOUTH SAN FRANCISCO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) today announced topline data from the approximately 400-participant sentinel

Trial Results • Phase 2Topline 12-month safety data Mon, Jul 6, 2026

Jul 1, 2026

Vaxart Enters Cooperation Agreement with Stockholder Group and Announces Board and Corporate Governance Enhancements

Company to Appoint Mutually Agreed Upon Independent Director; Forms Stockholder Engagement and Clinical and Regulatory Affairs Committees Stockholder Group Withdraws Director Nominations SOUTH SAN FRANCISCO, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc.

Jun 26, 2026

Vaxart Publishes Presentation Urging Shareholders to Vote “FOR” ALL Six of the Company’s Highly Qualified Director Nominees on the WHITE Proxy Card TODAY

Details Strategic Actions Taken by the Board to Advance the Company’s Pipeline and Drive Value Creation Vaxart’s Purpose-Built Board Brings the Proven Expertise Needed to Oversee its Next Phase of Growth Dissident Nominees Lack Relevant Clinical-Stage Biotech Expertise, Misrepresented Their

Jun 25, 2026

Vaxart Announces Update to BARDA Funding Award to Reflect Current Scope of COVID-19 Oral Pill Vaccine Trial

Latest Modification is Important Required Step to Releasing 12-month Data from 400-participant Sentinel Cohort Funding to Advance Data Analysis from More Than 5,000 Trial Participants Ahead of Key Trial Results SOUTH SAN FRANCISCO, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc.

Jun 16, 2026

Vaxart’s Two Newest Independent Directors James Breitmeyer, M.D., Ph.D., and Kevin Finney Send Letter to Shareholders Ahead of 2026 Annual Meeting

Urges Stockholders to Vote “FOR” ALL Six of Vaxart’s Director Nominees on the WHITE Proxy Card TODAY Visit Vote.Vaxart.com for Additional Information and Voting Resources SOUTH SAN FRANCISCO, Calif., June 16, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a

Jun 15, 2026

Vaxart to Showcase Oral Vaccine Platform and Strategic Vision at BIO 2026 and Taiwan Biotech Forum

SOUTH SAN FRANCISCO, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced that members of its management team will participate in two

Jun 9, 2026

Vaxart to Participate in BTIG Infectious Disease Day 2026

SOUTH SAN FRANCISCO, Calif., June 09, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced that members of the management team will participate in the

Jun 8, 2026

Vaxart Urges Shareholders to Vote “FOR” ALL Six of the Company’s Highly Qualified Director Nominees on the WHITE Proxy Card TODAY

Mails Letter to Shareholders Detailing Strength of the Board’s Nominees and Momentum in Advancing Vaxart’s Value Creation Strategy Reinforces that the Dissident’s Nominees Have No Relevant Biotechnology or Public Company Leadership Experience and Their Appointment to the Board Would Be Value

Jun 1, 2026

Vaxart Files Definitive Proxy Statement and Mails Letter to Shareholders

Emphasizes Importance of Experienced Biotech Leadership as Vaxart Advances Clinical and Strategic Priorities with Multiple Value-Creating Milestones Ahead Highlights Significant Risk of Replacing Vaxart’s Highly Qualified Directors with Candidates Who Have No Relevant Expertise Urges Shareholders

May 19, 2026

Vaxart Files Preliminary Proxy Statement and Issues Open Letter to Shareholders

Company is Entering a Pivotal Phase to Demonstrate Value of its Unique Oral Vaccine Platform Emphasizes Need for the Right Board Leadership at Critical Strategic Juncture Encourages Shareholders to Visit Vote.Vaxart.com for Additional Information SOUTH SAN FRANCISCO, Calif., May 19, 2026 (GLOBE

May 7, 2026

Vaxart Provides Business Update and Reports First Quarter 2026 Financial Results

Topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial anticipated in Q2 2026 Cash, cash equivalents, and investments of $61.0 million as of March 31, 2026; runway into second quarter of 2027 Live stockholder fireside chat scheduled for May 8, 2026 at 4:30 p.m.

May 1, 2026

Vaxart to Host Stockholder Fireside Chat on May 8 at 4:30 p.m. ET

Company to report first quarter 2026 financial results on May 7 SOUTH SAN FRANCISCO, Calif., May 01, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) today announced that members of the Company’s senior management team will participate in a virtual fireside chat on Friday, May 8, 2026 at 4:30

Apr 23, 2026

Vaxart Appoints James Breitmeyer, M.D., Ph.D., to Board of Directors

Appointment strengthens Board’s clinical development and regulatory expertise as Vaxart advances its oral vaccine platform SOUTH SAN FRANCISCO, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral vaccines based on

Apr 17, 2026

Vaxart Announces Share Purchase Agreement for up to $25 Million with Lincoln Park Capital

SOUTH SAN FRANCISCO, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral vaccines based on its proprietary delivery platform, today announced that it has entered into a share purchase

Mar 12, 2026

Vaxart Provides Business Update and Reports Full Year 2025 Financial Results

Topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial anticipated early Q2 2026 Published positive clinical results in the first quarter of 2026 demonstrating oral norovirus vaccine candidate was safe and immunogenic in lactating women and resulted in passive transfer of

Mar 3, 2026

Vaxart to Host Upcoming Conference Calls

Full year 2025 business update and financial results conference call to be held March 12 at 4:30 p.m. ET Stockholder fireside chat to be held on March 13 at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will host two

Feb 18, 2026

Vaxart to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026

SOUTH SAN FRANCISCO, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral vaccines based on its proprietary delivery platform, today announced that members of the management team will present at the Oppenheimer 36th

Jan 15, 2026

Vaxart Publishes Positive Data for its Oral Bivalent Norovirus Candidate in Lactating Women and Their Infants

Vaccine was safe and well-tolerated and led to a significant increase in norovirus-specific antibodies in serum and breast milk Norovirus-specific IgA in infant stool correlated with breast milk IgA, suggesting passive transfer of immunity to breastfed infants and the potential for a new approach